Author

M. Reichert

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Assay:proteomics· 3 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

G. Schneider· 2 shared M. Wirth· 2 shared U. Keller· 2 shared A. Baluapuri· 1 shared A. Becker· 1 shared A. Bick· 1 shared A. Gomez-Brouchet· 1 shared A. Illendula· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. Schneider

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer

J. Doffo, S. A. Bamopoulos, H. Kose, F. Orben, M. Pons, A. T. den Dekker, R. W. W. Brouwer, A. Baluapuri, S. Habringer, M. Reichert, A. Illendula, O. H. Kramer, M. Schick, E. Wolf, W. F. J. van IJcken, , M. Wirth

The paper identifies RUNX1 inhibition as a strategy to induce NOXA-dependent apoptosis in pancreatic cancer, showing it blocks tumor growth in vivo and in organoids.

bioRxiv · Oct 21, 2021Cancer Biology

Autoantibodies against Progranulin and IL-1 receptor antagonist due to immunogenic posttranslational isoforms contribute to hyperinflammation in critically ill COVID-19

L. Thurner, N. Fadle, M. Bewarder, I. Kos, E. Regitz, O. Cetin, B. Thurner, Y. Fischer, T. Rixecker, K.-D. Preuss, C. Schormann, F. Neumann, S. Hartmann, T. Bock, D. Kaddu-Mulindwa, , S. Koerper

This study identifies autoantibodies against PGRN and IL-1-Ra in critical COVID-19 patients, linked to hyperphosphorylated isoforms and increased inflammation.

bioRxiv · Apr 23, 2021 · PreprintImmunology

Phosphoproteomics identifies PI3K inhibitor-selective adaptive responses in pancreatic cancer cell therapy and resistance

C. Cintas, T. Douche, Z. Dantes, E. Mouton-Barbosa, M.-P. Bousquet, C. Cayron, N. Therville, F. Pont, F. Ramos-Delgado, C. Guyon, B. Garmy-Susini, P. Cappello, O. Burlet-Schiltz, E. Hirsch, A. Gomez-Brouchet, , J. Guillermet-Guibert

This study identifies adaptive phosphoprotein responses to isoform-selective PI3K inhibitors in pancreatic cancer, showing that combination therapy can overcome resistance.

bioRxiv · Oct 8, 2020Cancer Biology

Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC

K. Lankes, Z. Hassan, M. J. Doffo, C. Schneeweis, S. Lier, R. Oellinger, R. Rad, O. H. Kraemer, U. Keller, D. Saur, M. Reichert, G. Schneider, M. Wirth

The paper identifies bortezomib as a potential therapy for MYC hyperactive pancreatic cancer by showing its sensitivity to proteasome inhibition.

bioRxiv · Jul 1, 2020Cancer Biology